Health ❯ Healthcare ❯ Medical Research ❯ Clinical Trials

Cancer Treatment

Single CAR T Infusion Clears Residual Disease in High-Risk Smoldering Myeloma Trial

Early, one-time CAR T shows promise to shift care for high-risk smoldering myeloma pending confirmation in larger trials.

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

Morning Immunotherapy Boosts Survival in Lung Cancer Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

OS Therapies Posts Significant 2-Year Survival Gain for OST-HER2 in Metastatic Osteosarcoma

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Pivekimab Sunirine Shows 85% Response Rate in BPDCN Trial

Avelumab and Cetuximab Combo Quadruples Progression-Free Survival in Advanced cSCC

LUT014 Gel Shows Promise in Reducing Severe Rash from Colorectal Cancer Therapy

Zongertinib Achieves Breakthrough in Treating HER2-Mutant Lung Cancer